Objectives: To develop a thioridazine/moxifloxacin-based combination regimen for treatment of pulmonary infection due to Mycobacterium avium-intracellulare complex (MAC) that kills bacteria faster than the standard treatment regimen.
Introduction
The slow-growing Mycobacterium avium complex (MAC) is responsible for causing more pulmonary disease than Mycobacterium tuberculosis in the United States. 1 The best treatment regimen for MAC remains an open question. 2, 3 Macrolides are the key drugs in the treatment of MAC, in combination with ethambutol, and often with rifabutin. 2 Elsewhere we have shown that even with this regimen, the sputum culture conversion (defined as at least two consecutive negative cultures) is around 50% after 6 months (bestcase scenario), and falls to a mere 22% for treatment duration greater than 1 year, which is the recommended duration. 4 In addition, the long duration of therapy of several years is a major disadvantage, especially given the side effects of drugs in the regimen. Clearly, new regimens that can treat pulmonary MAC in a few months are needed; a prerequisite would be rapid sterilization rates.
The most likely cause of failure of therapy is emergence of resistance to one or more drugs used in the combination. The emergence of acquired drug resistance is a process in which efflux pumps could play an important role to give bacteria the time to develop chromosomal mutations. 5 Recently we demonstrated that azithromycin resistance in MAC can be abrogated by the use of the efflux pump blocker thioridazine. 5 Moreover, thioridazine kills MAC, with pharmacokinetic/pharmacodynamic (PK/PD) studies identifying peak/MIC-driven efficacy. 6 Thioridazine monotherapy sterilized 5.0 log 10 cfu/mL in 5 days, which is unprecedented. We have also performed PK/PD studies of the fluoroquinolone moxifloxacin in the treatment of intracellular MAC and identified the best exposures for optimal microbial kill. 7 Here, we were interested in examining combinations of moxifloxacin and optimized thioridazine exposures, as well as thioridazine and macrolides, in the hollow-fibre system model of pulmonary MAC disease (HFS-MAC). [6] [7] [8] [9] However, since thioridazine has a high adverse event profile, mainly neurotoxicity and cardiotoxicity, we wanted to use a strategy of optimized thioridazine exposures administered as four intermittent doses upfront to ii43 J Antimicrob Chemother 2017; 72 Suppl 2: ii43-ii47 doi:10.1093/jac/dkx308 rapidly bring bacterial burden down and then stopping therapy, a rapid dominance approach (commonly known as 'shock and awe'). 10 
Materials and methods

Materials, reagents and bacterial strain
Mycobacterium avium-intracellulare (ATCC 700898) was purchased from the ATCC (Manassas, VA, USA). Prior to each experiment the stock cultures were grown to logarithmic growth phase (log-phase growth) in Middlebrook 7H9 broth supplemented with 10% OADC under shaking conditions at 37 C. Hollow-fibre cartridges were purchased from FiberCell (Frederick, MD). Heatinactivated FBS, RPMI 1640, thioridazine and ethambutol were purchased from Sigma-Aldrich (St Louis, MO, USA). Azithromycin and moxifloxacin were purchased from the Baylor University Medical Center pharmacy. MICs were determined as described previously. [5] [6] [7] 9 Thioridazine/moxifloxacin combination study in 24-well plates For each combination of paired antibiotics, there are concentrations at which the combination will show antagonism, and some concentrations at which there is synergy or additivity. 11, 12 To identify these zones of antagonism, synergy or additivity, we performed a study using seven different exposures of either thioridazine or moxifloxacin, combined with other concentrations of the second drug, in 24-well plates. This results in a rectangular array of concentrations in a '7%7' matrix. THP-1 cells were activated and became adherent, after which they were infected with MAC as described elsewhere, 11 and then co-incubated with thioridazine and moxifloxacin for 7 days at 37 C under 5% CO 2 . The thioridazine concentrations used were 0, 5, 10, 12.5, 15, 17.5 and 20 mg/L. The moxifloxacin concentrations used were 0, 0.5, 2, 4, 8, 12 and 16 mg/L. Thus, a total of 49 concentration combinations were tested in triplicate (i.e. 147 wells). After 7 days of coincubation, the cultures were washed twice in warm RPMI 1640 to remove drug and extracellular bacteria, and the THP-1 cells were lysed in PBS with Tween (PBS-T). The samples were serially diluted and bacteria were cultured on Middlebrook 7H10 agar with 10% OADC (hereafter called 'agar') at 37 C under 5% CO 2 for 14 days, after which colonies were counted. The experiment was performed twice.
Comparison of the different regimens in the HFS model
A detailed description of the HFS-MAC has been published elsewhere as well as in the accompanying papers.
6,7,9,13-15 THP-1 cells (ATCC TIB-202) were infected at a 1:1 multiplicity of infection and then washed, after which 20 mL of the infected THP-1 cells was inoculated into the peripheral compartment of each of 12 HFS-MAC. The systems were maintained at 37 C under 5% CO 2 with circulating RPMI 1640 supplemented with 2% FBS, in line with our observations of the effect of protein binding in a prior study. 6 The treatment regimens were all two-drug combinations ( Table 1) . The first regimen investigated was that of ethambutol plus azithromycin. Ethambutol was administered to give concentration-time profiles achieved by a human-equivalent dose of 15 mg/kg/day while azithromycin was administered to give concentration-time profiles achieved by a humanequivalent dose of 500 mg/day, daily for 28 days. 5, 9 Two other regimens (Regimen A and B) consisted of thioridazine plus a second agent: thioridazine was administered at a peak concentration (C max ) to MIC ratio of 0.88, which is the exposure identified in the '7%7' matrix study in the additivity range (see below), at a dose schedule associated with optimal kill, intermittently on days 0, 3, 7 and 10, and then stopped. 6 In Regimen A, the thioridazine was administered together with daily azithromycin (500 mg human equivalent) for the entire study duration. In Regimen B, the thioridazine was administered with daily moxifloxacin to achieve the concentration-time profiles encountered with a 400 mg dose in patients administered daily for 14 days, 7 an exposure identified in the '7%7' matrix study from zones of synergy and additivity, after which daily 500 mg human-equivalent azithromycin monotherapy was administered. Drugs were infused via a computer-controlled syringe pump and the central compartments were sampled at 0, 1, 2, 6, 12, 18 and 23.5 h after first dose, after which the concentrations of each drug were measured using assays described previously. [5] [6] [7] 9 Peripheral compartments were sampled on days 0, 7, 14, 21 and 28 and the samples were processed as described above to determine the total number of viable THP-1 cells as well as to enumerate the bacterial burden in each system. Bacterial burden was identified by cultures on agar, and colonies counted as described above.
Statistical analyses
MacSynergy II program, which implements the Bliss independence model, was used to calculate the effect of the thioridazine and moxifloxacin interactions in 24-well plates. [16] [17] [18] The microbial effect of thioridazine and moxifloxacin at each drug concentration as monotherapy was used to calculate a theoretical additive effect of drug concentration combination pairs (i.e. microbial kill by drug A plus microbial kill by drug B). Next, the microbial kill identified in the experiment (i.e. observed effect) of each combination of concentrations minus the theoretical or calculated additivity effect was calculated. This creates a whole surface of observed effect minus the expected additivity effect across all the concentration ranges, which was used to calculate an interaction factor. A positive interaction factor, with 95% CI above zero, defined the synergy, whereas a negative interaction factor with 95% CI below zero represents antagonism. If observed minus expected is zero, then observed equals exactly the expected additivity (i.e. 95% CI crosses zero), which indicates additivity. The values were then transferred to SigmaPlot version 13 (Systat Software, San Jose, CA, USA) to generate a three-dimensional exposure-effect surface diagram with dimensions of moxifloxacin concentration, thioridazine concentration and interaction factor.
Statistical analyses also involved calculation of mean + SD of counts on each sampling day in the HFS-MAC. We also calculated the slopes of bacterial burden versus time in days for maximal kill rates. We wanted to test the null hypothesis that the mean values of log 10 cfu/mL on each sampling day for each of the regimens was statistically equal to the mean log 10 cfu/mL on that day in the azithromycin/ethambutol dual therapy, hereafter referred to as the standard regimen. Therefore, we performed a one-way analysis of variance (ANOVA) on each day at each sampling point. For the Srivastava et al.
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number of viable THP-1 cells, we performed a two-way ANOVA to determine the proportion of variation in the cell count due to regimen versus that due to duration of therapy.
Results
For our laboratory MAC strain, the MICs were 8, 32, 1 and 25 mg/L for ethambutol, azithromycin, moxifloxacin and thioridazine, respectively. Figure 1 shows the results of the interaction of thioridazine and moxifloxacin in the '7%7' matrix in 24-well plates. The zones of antagonism, identified as a negative interaction factor, are shown as depressions (deep blue colour) in Figure 1 , whereas the zones of synergy are shown as peaks (in red), having a positive interaction factor. Finally, zones of additivity for which the 95% CI crossed zero for the interaction factor are shown as a flat surface in Figure 1 . Based on these results, we chose a C max /MIC ratio of thioridazine in the synergy zone of 0.8 and moxifloxacin AUC 0-24 /MIC of 36 achieved by concentrations in the synergy zone shown in Figure 1 for the HFS-MAC studies. Two HFS-MAC studies were performed and yielded similar results; we report the combined results. Figure 2 shows the numbers of THP-1 cells on each day of sampling in the replicates. Treatment regimen accounted for only 4.3% of the variation (P " 0.002) in ANOVA of THP-1 cell counts, indicating no large difference between different regimens and no-drug-treated systems in cell viability. This suggests that none of the regimens were associated with killing of the infected human-derived cells. Figure 3 shows that MAC grew from 4.82+0.09 to 7.84+0.02 log 10 cfu/mL or a kill rate of # 0.11+0.01 log 10 cfu/mL/day in 28 days (r 2 " 0.95), in non-treated HFS-MAC replicates. The regimen of ethambutol and azithromycin killed 1.21+0.74 log 10 cfu/mL over the first 7 days of the therapy, after which bacterial burden started to increase, demonstrating failure. The maximum bacterial kill rate was 0.20+0.02 log 10 cfu/mL/day during the first 7 days (r 2 " 0.93). Regimen B with the four-dose thioridazine therapy plus daily azithromycin killed 3.70+0.68 log 10 cfu/mL during the first 7 days at a maximal kill rate of 0.23+0.04 log 10 cfu/mL/day (r 2 " 0.78), but failed during the azithromycin monotherapy phase beyond day 10. The most dramatic results were observed with Regimen A of thioridazine Figure 3 . Comparison of the different treatment regimens. There are six replicates (+SD) at each sampling time point. Regimens A and B with intermittent thioridazine dosing outperformed the dual ethambutol/ azithromycin regimen, the backbone of standard therapy. The limit of detection was 0.3 log 10 cfu/mL, and thus the 'zero' value for Regimen A on day 7 simply means below limits of detection. Indeed, the figure shows that there was regrowth in that regimen. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
A regimen associated with dramatic kill of MAC JAC ii45 and moxifloxacin. Figure 3 shows that with the four-dose thioridazine plus daily moxifloxacin for 14 days, Regimen B killed MAC to below limits of detection of our cfu/mL assay within 7 days; the maximum kill rate was 0.69+0.01 log 10 cfu/mL/day (r 2 . 0.99). However, the bacterial burden started to increase after stopping the thioridazine on day 10 and moxifloxacin on day 14. ANOVAs for each sampling time point compared with the standard ethambutol/azithromycin regimen log 10 cfu/mL differences are shown in Table 2 . The table shows that the effect of the ethambutol/azithromycin regimen was transient, and the intermittent thioridazine regimens had lower bacterial burdens by the end of the study than the azithromycin/ethambutol regimen.
Discussion
First, we found that the combination of intermittent thioridazine and daily moxifloxacin exhibits significant bactericidal activity against intracellular MAC in the HFS-MAC. Within 7 days, this regimen achieved bacterial burden below the limit of detection of our assay (0.3 log 10 cfu/mL). Indeed, this recapitulates the effect of optimal PK/PD exposures and dose schedule (C max /MIC is maximized by intermittent doses) seen previously with thioridazine monotherapy in the HFS-MAC. 6 This approach is akin to the military strategy known as 'rapid dominance' or more commonly 'shock and awe', in which dramatically high levels of force are used immediately as the war starts, employing the most destructive ordinances available to rapidly neutralize the adversary's military power. 10 Unfortunately, after the upfront delivery and the intermittent administration of thioridazine was stopped, there was regrowth. Thioridazine's high toxicity profile means that to achieve these high concentrations only a few doses of this drug can be administered, and even the safety of those few doses would need to be carefully documented. On the other hand, azithromycin continuous therapy failed to eliminate the remaining bacterial burden. The lesson is that if a second highly effective molecule is added in the PK/PD optimized manner we have described elsewhere, 19, 20 after the rapid fall in the viable bacterial count, the bacterial burden could be kept below the lower limit of detection. Thus, our results are a proof of principle.
Second, in the current study we found the same rates of kill by the azithromycin/ethambutol regimen as in a prior study. 21 This demonstrates consistency of the failure of that regimen in the treatment of HFS-MAC. In an accompanying paper in this series, we found that addition of rifabutin as a third drug improved the azithromycin/ethambutol regimen to 2.1 log 10 cfu/mL kill below the starting bacterial burden on day 14, but also failed beyond that. 15 This performance would still be poorer than even the intermittent thioridazine and azithromycin regimen we describe here. Thus, the failure of the azithromycin/ethambutol regimen is reproducible, and is not because we did not add a rifamycin. The failure is likely due to emergence of resistance; however, since MAC forms biofilms in bronchial epithelial cells, antibiotic tolerance from nonreplicating persistent bacteria could also be an explanation. These possibilities will be studied in future.
Despite the promising efficacy of the thioridazine/moxifloxacin combination, our study has some limitations. We used only one laboratory strain of MAC. It would be interesting to see how this regimen would perform against a large array of clinical strains with a wide MIC distribution, and our group has planned such future studies. However, given the toxicity of thioridazine, this was a proof of principle study, and the one isolate studied was sufficient for the demonstration. Finally, further experiments are needed to identify a less toxic backbone regimen for the treatment of MAC that would also have the possibility of rapidly bringing down the MAC burden within a few days.
In summary, thioridazine and moxifloxacin demonstrated synergy in specific thioridazine concentration ranges. The thioridazine/ moxifloxacin regimen that achieved the same exposures had a faster kill rate compared with the current standard drug combination used to treat pulmonary MAC. This shows that it is possible to develop an effective short-course treatment regimen that would rapidly sterilize pulmonary MAC.
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